rs1057910

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_000771.4(CYP2C9):​c.1075A>C​(p.Ile359Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0634 in 1,613,890 control chromosomes in the GnomAD database, including 3,705 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as drug response,other (★★).

Frequency

Genomes: 𝑓 0.049 ( 244 hom., cov: 32)
Exomes 𝑓: 0.065 ( 3461 hom. )

Consequence

CYP2C9
NM_000771.4 missense

Scores

1
17

Clinical Significance

drug response; other criteria provided, multiple submitters, no conflicts O:11

Conservation

PhyloP100: 0.278

Publications

1035 publications found
Variant links:
Genes affected
CYP2C9 (HGNC:2623): (cytochrome P450 family 2 subfamily C member 9) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0023085773).
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.106 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CYP2C9NM_000771.4 linkc.1075A>C p.Ile359Leu missense_variant Exon 7 of 9 ENST00000260682.8 NP_000762.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CYP2C9ENST00000260682.8 linkc.1075A>C p.Ile359Leu missense_variant Exon 7 of 9 1 NM_000771.4 ENSP00000260682.6
CYP2C9ENST00000643112.1 linkn.*84A>C non_coding_transcript_exon_variant Exon 6 of 8 ENSP00000496202.1
CYP2C9ENST00000643112.1 linkn.*84A>C 3_prime_UTR_variant Exon 6 of 8 ENSP00000496202.1

Frequencies

GnomAD3 genomes
AF:
0.0495
AC:
7523
AN:
152122
Hom.:
245
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0126
Gnomad AMI
AF:
0.0296
Gnomad AMR
AF:
0.0491
Gnomad ASJ
AF:
0.0827
Gnomad EAS
AF:
0.0307
Gnomad SAS
AF:
0.114
Gnomad FIN
AF:
0.0558
Gnomad MID
AF:
0.0728
Gnomad NFE
AF:
0.0662
Gnomad OTH
AF:
0.0526
GnomAD2 exomes
AF:
0.0631
AC:
15849
AN:
251154
AF XY:
0.0682
show subpopulations
Gnomad AFR exome
AF:
0.0123
Gnomad AMR exome
AF:
0.0381
Gnomad ASJ exome
AF:
0.0841
Gnomad EAS exome
AF:
0.0337
Gnomad FIN exome
AF:
0.0626
Gnomad NFE exome
AF:
0.0685
Gnomad OTH exome
AF:
0.0630
GnomAD4 exome
AF:
0.0649
AC:
94818
AN:
1461650
Hom.:
3461
Cov.:
32
AF XY:
0.0662
AC XY:
48127
AN XY:
727130
show subpopulations
African (AFR)
AF:
0.0127
AC:
425
AN:
33468
American (AMR)
AF:
0.0396
AC:
1767
AN:
44666
Ashkenazi Jewish (ASJ)
AF:
0.0833
AC:
2176
AN:
26124
East Asian (EAS)
AF:
0.0301
AC:
1196
AN:
39698
South Asian (SAS)
AF:
0.110
AC:
9478
AN:
86258
European-Finnish (FIN)
AF:
0.0627
AC:
3349
AN:
53412
Middle Eastern (MID)
AF:
0.0732
AC:
422
AN:
5764
European-Non Finnish (NFE)
AF:
0.0649
AC:
72123
AN:
1111880
Other (OTH)
AF:
0.0643
AC:
3882
AN:
60380
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
5603
11206
16808
22411
28014
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2604
5208
7812
10416
13020
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0494
AC:
7516
AN:
152240
Hom.:
244
Cov.:
32
AF XY:
0.0499
AC XY:
3715
AN XY:
74432
show subpopulations
African (AFR)
AF:
0.0125
AC:
521
AN:
41556
American (AMR)
AF:
0.0490
AC:
749
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
0.0827
AC:
287
AN:
3472
East Asian (EAS)
AF:
0.0307
AC:
159
AN:
5172
South Asian (SAS)
AF:
0.114
AC:
551
AN:
4828
European-Finnish (FIN)
AF:
0.0558
AC:
592
AN:
10608
Middle Eastern (MID)
AF:
0.0646
AC:
19
AN:
294
European-Non Finnish (NFE)
AF:
0.0662
AC:
4503
AN:
68004
Other (OTH)
AF:
0.0511
AC:
108
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
363
727
1090
1454
1817
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
96
192
288
384
480
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0613
Hom.:
1022
Bravo
AF:
0.0462
TwinsUK
AF:
0.0612
AC:
227
ALSPAC
AF:
0.0633
AC:
244
ESP6500AA
AF:
0.0143
AC:
63
ESP6500EA
AF:
0.0659
AC:
567
ExAC
AF:
0.0636
AC:
7727
Asia WGS
AF:
0.0770
AC:
268
AN:
3478
EpiCase
AF:
0.0713
EpiControl
AF:
0.0737

ClinVar

Significance: drug response; other
Submissions summary: Other:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Warfarin response Other:3
Aug 31, 2010
Pharmacogenomics Lab, Chungbuk National University
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:research

- likely responsive

Jun 15, 2012
OMIM
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:literature only

- -

-
Faculty of Pharmacy, Damascus University
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:research

rs1057910 is a SNP in the CYP2C9 gene and is linked to poor warfarin metabolism and risk of GI bleeding with warfarin, rs1057910 is associated with reduced enzyme activity and lower clearance rates of warfarin leading to higher rates of warfarin concentration likely responsive

Phenytoin response Other:2
Sep 24, 2020
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:case-control

May cause toxicity/ADR and poor metabolism/PK No CYP2C9 function

Jun 15, 2012
OMIM
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Piroxicam response Other:1
Feb 11, 2019
Medical Genetics Summaries
Significance:drug response
Review Status:criteria provided, single submitter
Collection Method:curation

Individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) have reduced clearance of piroxicam. Because the standard recommended dose of piroxicam may cause abnormally high plasma levels, a dose reduction should be considered for these individuals. Poor metabolizer

Glipizide response Other:1
Jun 15, 2012
OMIM
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Lesinurad response Other:1
Feb 11, 2019
Medical Genetics Summaries
Significance:drug response
Review Status:criteria provided, single submitter
Collection Method:curation

Lesinurad should be used with caution in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) because of increased exposure and an increased risk of side effects. Poor metabolizer

not provided Other:1
Jul 10, 2015
Eurofins Ntd Llc (ga)
Significance:other
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles).

Tolbutamide response Other:1
Dec 30, 2010
OMIM
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Flurbiprofen response Other:1
Feb 11, 2019
Medical Genetics Summaries
Significance:drug response
Review Status:criteria provided, single submitter
Collection Method:curation

The dose of flurbiprofen should be reduced in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) to avoid abnormally high plasma levels due to reduced metabolic clearance. Poor metabolizer

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.15
BayesDel_addAF
Benign
-0.51
T
BayesDel_noAF
Benign
-0.42
CADD
Benign
17
DANN
Benign
0.96
DEOGEN2
Benign
0.096
T
Eigen
Benign
-0.74
Eigen_PC
Benign
-0.74
FATHMM_MKL
Benign
0.090
N
LIST_S2
Benign
0.41
T
MetaRNN
Benign
0.0023
T
MetaSVM
Benign
-0.92
T
MutationAssessor
Benign
1.8
L
PhyloP100
0.28
PrimateAI
Benign
0.36
T
PROVEAN
Benign
-1.6
N
REVEL
Benign
0.070
Sift
Uncertain
0.013
D
Sift4G
Benign
0.36
T
Polyphen
0.0020
B
Vest4
0.085
MPC
0.019
ClinPred
0.011
T
GERP RS
1.1
Varity_R
0.64
gMVP
0.039
Mutation Taster
=87/13
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1057910; hg19: chr10-96741053; COSMIC: COSV53247682; API